CIK 0001719714 · Non-accelerated filer<br>Smaller reporting company
Mereo BioPharma Group plc
Sign in to watch- Ticker
- MREO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- United Kingdom
- Entity type
- operating
- Phone
- 4403330237300
- Business address
- ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, United Kingdom, W1G 0QF
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-05 | WYZGA MICHAEL S Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | WYZGA MICHAEL S Director | Grant or award · Deferred Restricted Stock Units | +30,487 | 30,487 | ||
| 2025-02-05 | Jenkins Annalisa Director | Grant or award · Share Options (Right to buy) | +55,000 | 55,000 | ||
| 2025-02-05 | Jenkins Annalisa Director | Grant or award · Deferred Restricted Stock Units | +15,243 | 15,243 | ||
| 2025-01-25 | Lewicki John A. Chief Scientific Officer | Grant or award · Share Options (Right to buy) | +116,000 | 116,000 | ||
| 2025-01-25 | Fox Christine Ann Chief Financial Officer | Grant or award · Share Options (Right to buy) | +262,000 | 262,000 | ||
| 2025-01-25 | Sermon Charles General Counsel | Grant or award · Share Options (Right to buy) | +262,000 | 262,000 | ||
| 2025-01-25 | Hughes-Wilson Alexandra See Remarks | Grant or award · Share Options (Right to buy) | +154,000 | 154,000 | ||
| 2025-01-25 | Scots-Knight Denise Chief Executive Officer | Grant or award · Share Options (Right to buy) | +825,000 | 825,000 | ||
| 2024-09-13 | Scots-Knight Denise Chief Executive Officer | Sale | −60,046 | $4.22 | $253K | 808,921 |
| 2024-09-13 | Lewicki John A. Chief Scientific Officer | Sale | −10,937 | $4.22 | $46K | 78,630 |
| 2024-09-13 | Sermon Charles General Counsel | Sale | −20,946 | $4.22 | $88K | 219,061 |
| 2024-09-13 | Fox Christine Ann Chief Financial Officer | Sale | −19,158 | $4.22 | $81K | 89,285 |
| 2024-09-13 | Hughes-Wilson Alexandra See Remarks | Sale | −16,304 | $4.22 | $69K | 134,483 |
| 2024-09-13 | Hughes-Wilson Alexandra See Remarks | Sale | −84,008 | $4.22 | $355K | 50,475 |
| 2024-09-12 | Scots-Knight Denise Chief Executive Officer | Sale | −28,611 | $4.47 | $128K | 868,967 |
| 2024-09-12 | Lewicki John A. Chief Scientific Officer | Sale | −5,212 | $4.47 | $23K | 89,567 |
| 2024-09-12 | Sermon Charles General Counsel | Sale | −9,980 | $4.47 | $45K | 240,007 |
| 2024-09-12 | Fox Christine Ann Chief Financial Officer | Sale | −9,128 | $4.47 | $41K | 108,443 |
| 2024-09-12 | Hughes-Wilson Alexandra See Remarks | Sale | −7,769 | $4.47 | $35K | 190,816 |
Page 3 of 7 · 139 trades